Hazem Alhawasli, MD
Interventional Cardiology · New Lenox, ILNPI 1215287164
Payments from drug & device makers
What this record shows
This record is dominated by grants: $43,000 of the $55,523 with a category attached, or 77.4%. 19 manufacturers reported payments, led by Boston Scientific at 45.7% of the total. Reporting peaked in 2019 at $47,694 and has fallen 97.1% since, to $1,368 in 2025. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $276.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$25K
- Medtronic$20K
- Edwards Lifesciences$5K
- Abbott$5K
- E.r. Squibb & Sons, L.L.C.$154
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$151
- plus $577 from 13 others
What the payments were for
- Consulting fees$1180%
- Grants$43,00077%
- Travel & lodging$6,81512%
- Food & beverage$5,59010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $25,365 |
| Medtronic(2 entities) | 35 | $19,683 |
| Edwards Lifesciences | 44 | $4,998 |
| Abbott | 59 | $4,594 |
| E.r. Squibb & Sons, L.L.C. | 8 | $154 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $151 |
| Pfizer | 8 | $138 |
| Novartis | 5 | $86 |
| Terumo Medical Corporation | 1 | $69 |
| Scpharmaceuticals Inc. | 3 | $64 |
| Merck | 3 | $47 |
| Teleflex LLC | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Abiomed | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| EKOS Corporation | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL HEART$25,000
- CoreValve Evolut$18,118
- PASCAL$1,817
- Omnilink Elite vascular stent system$1,166
- EVOQUE$1,162
- COUGAR$859
- Xience V coronary stent system$434
- Edwards SAPIEN 3 Transcatheter Heart Valve$213
- NAVITOR$153
- Mitra Clip system$148
- Optis Coronary Imaging System$147
- AMPLATZER AMULET$131
How this compares
$55,523 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 267 | $246,055 |
| EntrestoSacubitril/Valsartan | 156 | $227,108 |
| JardianceEmpagliflozin | 144 | $173,260 |
| BrilintaTicagrelor | 156 | $112,970 |
| XareltoRivaroxaban | 28 | $34,298 |
| Atorvastatin Calcium | 522 | $6,287 |
| ClopidogrelClopidogrel Bisulfate | 267 | $3,970 |
| Ranolazine ErRanolazine | 16 | $2,958 |
| Metoprolol Succinate | 191 | $2,809 |
| Carvedilol | 253 | $2,308 |
| Furosemide | 301 | $1,994 |
| Potassium Chloride | 111 | $1,862 |
| Amiodarone Hcl | 70 | $1,826 |
| Midodrine Hcl | 32 | $1,825 |
| Amlodipine Besylate | 159 | $1,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $246,055267 claims |
| NovartisEntresto | $86 | $227,108156 claims |
| Boehringer IngelheimJardiance | $23 | $173,260144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in New Lenox
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.